Hepatologie 2007

Was ist neu?

• Virushepatitis: Entecavir und Tenofovir bei Hepatitis B; Hepatitis-C: Impfung im Tiertest. Individuelle Therapiedauer. Hepatitis-E-Vakzine im Test

• NASH: Ist Pioglitazon wirksam?

• Leberzirrhose: Fibro-Scan, Enzephalopathie frühzeitig therapieren. Neue Therapie bei Hyponatriämie?

• Cholestase: Sertralin bei Pruritus

• Hepatozelluläres Karzinom: Studien zu medikamentöser Therapie laufen.

• Transplantation: Neuer Score zur Priorisierung

Literatur

• 1 Abou-Alfa G K, Schwartz L, Ricci S. et al . Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2006;  24 4293-4300
• 2 Belfort R, Harrison S A, Brown K. et al . A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355 2297-2307
• 3 Berg T, von Wagner M, Nasser S. et al . Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.  Gastroenterology. 2006;  130 1086-1097
• 4 Chang T T, Gish R G, de Man R. et al . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2006;  354 1001-1010
• 5 Chen C J, Yang H I, Su J. et al . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295 65-73
• 6 Ekstedt M. et al . Long-term follow-up of patients with NAFLD and elevated liver enzymes.  Hepatology. 2006;  44 865-873
• 7 Erhardt A, Lorke J. et al . Transient elastography for diagnosing liver cirrhosis.  Dtsch Med Wochenschr. 2006;  131 2765-1759
• 8 Folgori A, Capone S, Ruggeri L. et al . A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.  Nat Med. 2006;  12 190-197
• 9 Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis.  Hepatology. 2006;  43 1187-1190
• 10 Iloeje U H, Yang H I, Su J. et al . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.  Gastroenterology. 2006;  130 678-686
• 11 Kamath P S, Kim W R. The model for end-stage liver disease (MELD).  Hepatology. 2007;  45 797-805
• 12 Lai C L, Shouval D, Lok A S. et al . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2006;  354 1011-1020
• 13 Lok A S, McMahon B J. Chronic hepatitis B.  Hepatology. 2007;  45 507-539
• 14 Mayo M J, Handem I, Saldana S. et al . Sertraline as a first-line treatment for cholestatic pruritus.  Hepatology. 2007;  45 666-674
• 15 Ota T, Takamura T, Kurita S. et al . Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.  Gastroenterology. 2007;  132 282-293
• 16 Otto G, Herber S, Heise M. et al . Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.  Liver Transpl. 2006;  12 1260-1267
• 17 Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.  Gastroenterology. 2006;  130 715-720
• 18 Prasad S, Dhiman R K. et al . Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.  Hepatology. 2007;  45 549-559
• 19 Rapti I, Dimou E et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.  Hepatology. 2007;  45 307-313
• 20 Sarrazin C, Rouzier R, Wagner F. et al . SCH 503 034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.  Gastroenterology. 2007;  132 1270-1278
• 21 Schrier R W, Gross P, Gheorghiade M. et al . Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.  N Engl J Med. 2006;  355 2099-2112
• 22 Sherman M, Yurdaydin C. et al . Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.  Gastroenterology. 2006;  130 2039-2049
• 23 Shrestha M P, Scott R M. et al . Safety and efficacy of a recombinant hepatitis E vaccine.  N Engl J Med. 2007;  356 895-903
• 24 Sudan D L. Transplantation for cholangiocarcinoma.  Liver Transpl. 2006;  12 S83-84
• 25 van Bommel F, Zollner B, Sarrazin C. et al . Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.  Hepatology. 2006;  44 318-325
• 26 Wedemeyer H, Cornberg M, Wiegand J, Manns M. Treatment duration in acute hepatitis C: the issue is not solved yet.  Hepatology. 2006;  44 1051
• 27 Zeuzem S, Buti M, Ferenci P. et al . Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.  J Hepatol. 2006;  44 97-103
• 28 Kettaneh A, Marcellin P, Douvin C. et al . Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients.  J Hepatol. 2007;  46 628-634